The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups
Open accessAbstract
// Michele Simbolo 1,2,* , Matteo Fassan 1,2,* , Andrea Ruzzenente 3,* , Andrea Mafficini 1 , Laura D. Wood 4 , Vincenzo Corbo 1 , Davide Melisi 5 , Giuseppe Malleo 6 , Caterina Vicentini 1 , Giorgio Malpeli 1,3,6 , Davide Antonello 1,3,6 , Nicola Sperandio 1 , Paola Capelli 2 , Anna Tomezzoli 2 , Calogero Iacono 3 , Rita T. Lawlor 1,2 , Claudio Bassi 6 , Ralph H. Hruban 4 , Alfredo Guglielmi 3 , Giampaolo Tortora 5 , Filippo de Braud 7 , Aldo Scarpa 1,2 1 ARC-Net Research Centre, University and Hospital Trust of Verona, Verona, Italy 2 Department of Pathology and Diagnostics, University and Hospital Trust of Verona, Verona, Italy 3 Department of Surgery, General Surgery A, University of Verona, Verona, Italy 4 Department of Pathology, Johns Hopkins University and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA 5 Department of Medical Oncology, University and Hospital Trust of Verona, Verona, Italy 6 Department of Surgery, General Surgery B, University of Verona, Verona, Italy 7 Medical Oncology Unit 1, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy * shared first authorship Correspondence: Aldo Scarpa, email: // Keywords : cholangiocarcinoma; next-generation sequencing; molecular subclassification; target therapy; multigene mutational panels Received : April 2, 2014 Accepted : April 30, 2014 Published : May 1, 2014 Abstract One-hundred-fifty-three biliary cancers, including 70 intrahepatic cholangiocarcinomas (ICC), 57 extrahepatic cholangiocarcinomas (ECC) and 26 gallbladder carcinomas (GBC) were assessed for mutations in 56 genes using multigene next-generation sequencing. Expression of EGFR and mTOR pathway genes was investigated by immunohistochemistry. At least one mutated gene was observed in 118/153 (77%) cancers. The genes most frequently involved were KRAS (28%), TP53 (18%), ARID1A (12%), IDH1/2 (9%), PBRM1 (9%), BAP1 (7%), and PIK3CA (7%). IDH1/2 (p=0.0005) and BAP1 (p=0.0097) mutations were characteristic of ICC, while KRAS (p=0.0019) and TP53 (p=0.0019) were more frequent in ECC and GBC. Multivariate analysis identified tumour stage and TP53 mutations as independent predictors of survival. Alterations in chromatin remodeling genes ( ARID1A , BAP1 , PBRM1 , SMARCB1 ) were seen in 31% of cases. Potentially actionable mutations were seen in 104/153 (68%) cancers: i) KRAS/NRAS/BRAF mutations were found in 34% of cancers; ii) mTOR pathway activation was documented by immunohistochemistry in 51% of cases and by mutations in mTOR pathway genes in 19% of cancers; iii) TGF-ß/Smad signaling was altered in 10.5% cancers; iv) mutations in tyrosine kinase receptors were found in 9% cases. Our study identified molecular subgroups of cholangiocarcinomas that can be explored for specific drug targeting in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Borger, D. R., Tanabe, K. K., Fan, K. C., Lopez, H. U., Fantin, V. R., Straley, K. S., Schenkein, D. P., Hezel, A. F., Ancukiewicz, M., Liebman, H. M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0386 · Cited by 728
Cited by
Banales, J. M., Cardinale, V., Carpino, G., Marzioni, M., Andersen, J. B., Invernizzi, P., Lind, G. E., Folseraas, T., Forbes, S. J., Fouassier, L., et al. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.51 · Cited by 1,376
Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
Sia, D., Villanueva, A., Friedman, S. L., & Llovet, J. M. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.11.048 · Cited by 1,153
Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise
Saha, S. K., Zhu, A. X., Fuchs, C. S., & Brooks, G. A. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0446 · Cited by 786
Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations
Wardell, C. P., Fujita, M., Yamada, T., Simbolo, M., Fassan, M., Karlic, R., Polak, P., Kim, J., Hatanaka, Y., Maejima, K., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.01.009 · Cited by 373
Self-citationSia, D., Losic, B., Moeini, A., Cabellos, L., Hao, K., Revill, K., Bonal, D., Miltiadous, O., Zhang, Z., Hoshida, Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms7087 · Cited by 311
Metadata
- Authors
- Simbolo, M., Fassan, M., Ruzzenente, A., Mafficini, A., Wood, L. D., Corbo, V., Melisi, D., Malleo, G., Vicentini, C., Malpeli, G., Antonello, D., Sperandio, N., Capelli, P., Tomezzoli, A., Iacono, C., Lawlor, R. T., Bassi, C., Hruban, R. H., Guglielmi, A., Tortora, G., de Braud, F., & Scarpa, A.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2014-05-01
- Volume
- 5
- Issue
- 9
- Pages
- 2839-2852
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1806572515
- Cited by
- 209
- References
- 1
- FWCI
- 19.12
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. https://app.cochat.ai/papers/10.18632/oncotarget.1943
- The paper
- Simbolo, M., Fassan, M., Ruzzenente, A., Mafficini, A., Wood, L. D., Corbo, V., Melisi, D., Malleo, G., Vicentini, C., Malpeli, G., Antonello, D., Sperandio, N., Capelli, P., Tomezzoli, A., Iacono, C., Lawlor, R. T., Bassi, C., Hruban, R. H., Guglielmi, A., . . . Scarpa, A. (2014). Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget. https://doi.org/10.18632/oncotarget.1943
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.